Stepan Company (SCL) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
9 Aug, 2026Executive summary
Adjusted EBITDA for Q2 2026 reached $74.4 million, up 45% year-over-year, driven by broad-based volume growth, margin recovery, and Project Catalyst savings.
Net sales rose 15% to $684.1 million, reflecting higher prices, volumes, favorable mix, and currency translation.
Adjusted net income was $27.1 million ($1.18 per diluted share), up 126% year-over-year.
Strong safety performance was highlighted, with the best record in the past 12 months.
Project Catalyst restructuring led to significant charges in H1 2026 and included a reduction of approximately 100 salaried positions and multiple site closures.
Financial highlights
Gross profit for Q2 2026 increased to $100.0 million from $71.9 million year-over-year.
Operating income for Q2 2026 rose to $37.2 million from $18.0 million in Q2 2025.
Free cash flow was negative $15.0 million, impacted by a $58 million working capital build and $23.4 million in capital expenditures.
Net leverage ratio improved to 2.5x from 2.9x a year ago; net debt at $534 million and net debt to capital at 31%.
Adjusted EBITDA margin for Q2 was 10.9%, up from 8.6% in the prior year.
Outlook and guidance
Project Catalyst expected to deliver ~$100 million in pre-tax savings over two years, with $22 million quarterly run rate targeted by year-end and 60% realized in 2026.
Full-year 2026 restructuring charges are projected at $75–80 million, with $4–6 million related to Q3 workforce reduction and a cash impact of $14–18 million.
2026 capital expenditures forecasted at $100–110 million; scheduled debt repayments of $59 million and effective tax rate of 24–26%.
Management expects continued adjusted EBITDA growth, positive free cash flow, and further deleveraging in 2026.
Q3 EBITDA expected to be slightly lower than Q2 due to normalization of volumes and margins; some Q2 demand was pulled forward due to customer pre-buying amid geopolitical and raw material uncertainty.
Latest events from Stepan Company
- Net loss of $41.4M driven by restructuring, with adjusted EBITDA down 14% and sales up 2%.SCL
Q1 2026 - 2025 results highlight diversified growth, operational excellence, and a robust innovation pipeline.SCL
Investor presentation - Proxy covers director elections, pay practices, auditor ratification, and strong governance.SCL
Proxy filing - Adjusted EBITDA grew 6% in 2025; Project Catalyst targets $100M in savings, with H2 2026 recovery expected.SCL
Q4 2025 - Key votes include director elections, executive pay, auditor ratification, and equity plan expansion.SCL
Proxy Filing - Q3 net income up 88% to $23.6M, EBITDA up 11%, with strong Surfactants and cost savings.SCL
Q3 2024 - Adjusted EBITDA grew 4% in Q2 2024 despite lower net income and significant one-time expenses.SCL
Q2 2024 - Net income up 42% and EBITDA up 12% on strong surfactant and specialty growth.SCL
Q1 2025 - Net income up 25% and adjusted EBITDA rose 4%, with Pasadena facility to boost 2025 growth.SCL
Q4 2024